Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts said.

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

Moderna stock is under pressure, again, as Robert F. Kennedy Jr. reportedly mulls pulling the company's federal funding to ...

Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.

Pfizer appoints former J&J executive to lead obesity drug development Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...

Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established rivals ...

Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or refractory multiple myeloma (RRMM) at ASCO, previewing a future ...